Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,984.00
Bid: 1,983.00
Ask: 1,984.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.05%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,984.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

15 Jan 2020 09:44

RNS Number : 8766Z
Hikma Pharmaceuticals Plc
15 January 2020
 

1.1 Annex DTR3

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

All relevant boxes should be completed in block capital letters

1.

Name of the Issuer:

 

Hikma Pharmaceuticals PLC

2.

State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance with LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006):

DTR 3.1.2 R

3.

Name of person discharging managerial responsibilities/director:

Said Darwazah, Mazen Darwazah and Ali Al-Husry

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/ director named in 3 and identify the connected person:

Yes: Darhold Limited

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest:

Beneficial interest in Darhold Limited

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares:

Ordinary Shares

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them:

EFG Bank

8.

State the nature of the transaction:

Pledge of 2,345,000 Ordinary Shares in support of a loan

9.

Number of shares, debentures or financial instruments relating to shares acquired:

None

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage):

N/A

11.

Number of shares, debentures or financial instruments relating to shares disposed:

None

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage):

N/A

13.

Price per share or value of transaction:

N/A

14.

Date and place of transaction:

Amman, 15 January 2020

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage):

60,000,000 - 24.76 per cent.

16.

Date issuer informed of transaction:

15 January 2020

 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17.

Date of grant

18.

Period during which or date on which exercisable

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

24.

Name of contact and telephone number for queries

 

Name of authorised official or issuer responsible for making notification

Peter Speirs, Company Secretary, Hikma Pharmaceuticals PLC

Date of notification: 15 January 2020

 

Notes:

This form is intended for use by an issuer to make a RIS notification required by DTR 3.1.4

(1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGCGDBGSBDGGU
Date   Source Headline
19th Aug 20156:28 pmRNSDirector/PDMR Shareholding
19th Aug 20157:00 amRNSInterim Results
28th Jul 20157:00 amRNSAcquisition
14th Jul 201511:12 amRNSTotal Voting Rights
18th May 201510:30 amRNSHikma Founder Samih Darwazah passes away
18th May 201510:00 amRNSDirector/PDMR Shareholding
15th May 20151:25 pmRNSDirector/PDMR Shareholding
14th May 20154:27 pmRNSResult of AGM
14th May 20157:00 amRNSAGM Trading Update
12th May 20159:00 amRNSHikma launches caffeine citrate injection
15th Apr 20159:47 amRNSHolding(s) in Company
10th Apr 20153:19 pmRNSTotal Voting Rights
10th Apr 20157:00 amRNSDirector/PDMR Shareholding
9th Apr 201511:16 amRNSAnnual Information Update
9th Apr 201510:51 amRNSAnnual Financial Report
7th Apr 20153:03 pmRNSBlocklisting Interim Review
1st Apr 20155:13 pmRNSHikma prices debut $500 million five-year eurobond
31st Mar 20153:27 pmRNSStabilisation Notice
25th Mar 201512:23 pmRNSFixed income investor meetings
19th Mar 20151:45 pmRNSDirector/PDMR Shareholding
13th Mar 201511:34 amRNSHolding(s) in Company
11th Mar 20157:00 amRNSFinal Results
27th Jan 20152:13 pmRNSHikma Delivers Insights at World Economic Forum
23rd Jan 201511:44 amRNSDirector Declaration
21st Jan 201511:19 amRNSNotification of major interest in shares
15th Jan 201510:04 amRNSBlocklisting Interim Review
12th Jan 20157:00 amRNSHikma to launch colchicine 0.6mg capsules
7th Jan 201511:11 amRNSTotal Voting Rights
12th Nov 201412:14 pmRNSDirector/PDMR Shareholding
11th Nov 20141:22 pmRNSTotal Voting Rights
7th Nov 201411:12 amRNSNotification of major interest in shares
6th Nov 20147:00 amRNSDirectorate Change
6th Nov 20147:00 amRNSInterim Management Statement
24th Oct 20147:00 amRNSHikma announces receipt of Warning Letter from FDA
20th Oct 20145:18 pmRNSDirector/PDMR Shareholding
10th Oct 201411:44 amRNSStatement re Colchicine
10th Oct 20147:00 amRNSDirector/PDMR Shareholding
6th Oct 20143:58 pmRNSBlocklisting Interim Review
6th Oct 201411:23 amRNSTotal Voting Rights
30th Sep 20146:13 pmRNSRegulatory Approval Colchicine
17th Sep 20147:00 amRNSAcquisition
20th Aug 20144:00 pmRNSDividend Declaration
20th Aug 20147:00 amRNSInterim Results
7th Aug 20144:05 pmRNSNotice of Interim Results Announcement
28th Jul 20149:01 amRNSDirector/PDMR Shareholding
24th Jul 20149:08 amRNSAcquisition
15th Jul 20143:35 pmRNSAcquisition
14th Jul 20143:41 pmRNSTotal Voting Rights
27th Jun 20144:07 pmRNSDirector/PDMR Shareholding
23rd Jun 20142:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.